insights_auto
Why is AGIO down 4,03%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
27,60 $
arrow_downward
-4,03%(-1,16) 1D
27,60 $
0,00% (0,00)
bedtimeAfter hours
Closed: 20 қар., 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
28,01 $
High
29,14 $
Low
27,43 $
Mkt. cap
1,65 млрд
Avg. vol.
1,13 млн
Volume
776,16 м.
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
Open
28,01 $
High
29,14 $
Low
27,43 $
Mkt. cap
1,65 млрд
Avg. vol.
1,13 млн
Volume
776,16 м.
52-wk high
44,07 $
52-wk low
23,02 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 млн
No. of employees
540
News stories
From web sources and news partners
AP News
·
33 минут бұрын
S&P 500 sinks 3.7% and Nasdaq composite goes negative for the year as tech sell-off worsens
WSJ
·
13 сағат бұрын
S&P 500 Flirts With Correction
Barron's
·
4 сағат бұрын
S&P 500’s Tech Sector Crosses Bear Market Threshold
Los Angeles Times
·
5 сағат бұрын
S&P 500 falls 10% from record, entering correction as AI trade unravels
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc